| This major milestone represents a new revenue stream for the Company and positions Khiron’s European team to execute on its German medical strategy. Leveraging its partner’s large distribution network and Khiron’s ongoing investments in physician education, the Company has secured immediate access to the German market. Khiron 1/14 will focus on indications such as anxiety, substance use disorder, and migraines, addressing patient needs and improving access to medical cannabis. Tejinder Virk, President of Khiron Europe, commented, “Since signing our distribution agreement with Nimbus Health in 2020, the Company’s European Sales and Marketing teams have been actively educating doctors and raising awareness for our products. We are excited to launch our portfolio with Khiron 1/14, a product that covers unmet medical need in the German market. As we continue to expand our presence in the UK and Germany, we will leverage our clinical expertise from Colombia to provide the EU market with additional cannabis-based medicinal products.” Franziska Katterbach, Managing Director & Chief Legal Officer for Khiron Europe based in Frankfurt, commented, “I would like to thank our European team for their unwavering perseverance over the past few months; their efforts have allowed us to achieve this significant milestone despite the challenges of the global pandemic and Germany’s strict regulatory environment. With all permits in place and product now available for sale, we look forward to increasing our presence in this growing market with over 60,000 medical cannabis patients and a population of over 82 million people. We are already developing additional cannabis-based medicinal products from our certified strains recently imported from Colombia to improve access and product selection for German patients.” Through its EU-GMP certified supply chain partners in Europe, Khiron continues to expand its offering of world-class medical cannabis products, targeting the introduction of cannabis-based medicinal products based on those already distributed by the Company in Colombia and Peru. With Khiron’s proof of concept now validated in Colombia, the Company plans to leverage its clinical data and IP, educational platforms, and technology and systems to expand into new markets. Forward-Looking Statements This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. (This information is primarily sourced from Khiron. Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here) | 
